AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35045999 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy alone (HFNO or standard oxygen)
Number of subjects: 0
Study 34731916 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet use
Number of subjects: 100
Study 34731916 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood loss > 500 cm3
Number of subjects: 100
Study 34731916 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Hb < 10 g/dl
Number of subjects: 100
Study 34731916 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusions
Number of subjects: 100
Study 34731916 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 100
Study 32220517 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryogen®/BlastGen™ culture medium
Number of subjects: 100
Study 2000065592 — intervention group
Group type: EXPERIMENTAL
Intervention: Sultamicillin
Number of subjects: 82
Study 2000065592 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid
Number of subjects: 82
Study 35776182 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE with dicycloplatin alone (group A1)
Number of subjects: 71
Study 35776182 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE with dicycloplatin plus epirubicin (group A2)
Number of subjects: 71
Study 35776182 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin alone (group B)
Number of subjects: 71
Study 35776182 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 71
Study 33423006 — intervention group
Group type: EXPERIMENTAL
Intervention: gBRCA1/2 mutations
Number of subjects: 1171
Study 33423006 — intervention group
Group type: COMPARATOR
Intervention: wild-type
Number of subjects: 1171
Study 33423006 — intervention group
Group type: EXPERIMENTAL
Intervention: gBRCA1 mutations
Number of subjects: 1171
Study 34076370 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioural intervention (FBBI)
Number of subjects: 37
Study 34076370 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (control)
Number of subjects: 37
Study 34076370 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioural intervention with maintenance (FBBI-M)
Number of subjects: 37
Study 34076370 — intervention group
Group type: COMPARATOR
Intervention: Family-based behavioural intervention control (FBBI-C)
Number of subjects: 37
Study 32557305 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-based quality management approach in clinical trials with combination products
Number of subjects: 15
Study 32557305 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination products in clinical trials
Number of subjects: 15
Study 32557305 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrics for risks and quality management
Number of subjects: 15
Study 33530241 — intervention group
Group type: EXPERIMENTAL
Intervention: Training set (n = 1299)
Number of subjects: 1856
Study 33530241 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation set (n = 557)
Number of subjects: 1856
Study 33530241 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 1856
Study 32013045 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich meals until 13:30 and high-fat meals between 16:30 and 22:00
Number of subjects: 29
Study 32013045 — intervention group
Group type: COMPARATOR
Intervention: Inverse order of meals (high-fat meals until 13:30 and carbohydrate-rich meals between 16:30 and 22:00)
Number of subjects: 29
Study 35120544 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy High School (HHS) intervention
Number of subjects: 4577
Study 33606023 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard systemic therapy with comprehensive EPC service referral
Number of subjects: 90
Study 33606023 — intervention group
Group type: COMPARATOR
Intervention: Standard systemic therapy without EPC
Number of subjects: 90
Study 32604142 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care psychosocial interventions
Number of subjects: 290
Study 32604142 — intervention group
Group type: EXPERIMENTAL
Intervention: General Symptom Distress Scale
Number of subjects: 290
Study 34801348 — intervention group
Group type: EXPERIMENTAL
Intervention: Bespoke mobile application (My Retainers)
Number of subjects: 84
Study 34801348 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to mobile application)
Number of subjects: 84
Study 34801348 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 33048260 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotics (1 g of amoxicillin, twice daily for 7 days)
Number of subjects: 41
Study 33048260 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (control)
Number of subjects: 41
Study 32525474 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopy with 4g of talc poudrage
Number of subjects: 330
Study 32525474 — intervention group
Group type: COMPARATOR
Intervention: Chest drain insertion with 4g of talc slurry
Number of subjects: 330
Study 34996644 — intervention group
Group type: EXPERIMENTAL
Intervention: Message about cancer (HPV causes cervical cancers vs cancers in general)
Number of subjects: 1021
Study 34996644 — intervention group
Group type: EXPERIMENTAL
Intervention: Information that it protected against cancers in general
Number of subjects: 1021
Study 34996644 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing information about a sexually transmitted infection
Number of subjects: 1021
Study 34996644 — intervention group
Group type: EXPERIMENTAL
Intervention: Messaging
Number of subjects: 1021
Study 33781793 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon
Number of subjects: 212
Study 33781793 — intervention group
Group type: COMPARATOR
Intervention: Standard balloon
Number of subjects: 212
Study 35272757 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D training
Number of subjects: 40
Study 35272757 — intervention group
Group type: COMPARATOR
Intervention: 2D training
Number of subjects: 40
Study 33560235 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS group (motivational messages every 3 days for 6 months)
Number of subjects: 141
Study 33560235 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 141
Study 33560235 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS group
Number of subjects: 141
Study 33560235 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141
Study 36419818 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofunctional therapy (MT)
Number of subjects: 40
Study 36419818 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific exercises (Control)
Number of subjects: 40
Study 32144733 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based learning
Number of subjects: 413
Study 32144733 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture-based learning
Number of subjects: 413
Study 35914262 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT) with interoceptive exposure
Number of subjects: 0
Study 35679193 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Health StandingTall balance exercise programme
Number of subjects: 503
Study 35679193 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 503
Study 34222709 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based smoking cessation app
Number of subjects: 60
Study 34222709 — intervention group
Group type: COMPARATOR
Intervention: In-person mindfulness intervention
Number of subjects: 60
Study 34222709 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 34101716 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with vasopressors to maintain SBP within 10% of pre-operative values
Number of subjects: 230
Study 34101716 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 230
Study 32702867 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART initiation (≤14 days after TE diagnosis)
Number of subjects: 200
Study 32702867 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART (>14 days after TE diagnosis)
Number of subjects: 200
Study 34486577 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivinex iSert XY1 (ABC design)
Number of subjects: 85
Study 34486577 — intervention group
Group type: COMPARATOR
Intervention: AcrySof IQ SN60WF (posterior aspheric design)
Number of subjects: 85
Study 34486577 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IOLs
Number of subjects: 85
Study 33781218 — intervention group
Group type: EXPERIMENTAL
Intervention: High education level and full-time employment with mild physical activity
Number of subjects: 450
Study 33781218 — intervention group
Group type: COMPARATOR
Intervention: Low education level and part-time or no employment
Number of subjects: 450
Study 32154636 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilteritinib (120 mg once daily)
Number of subjects: 371
Study 32154636 — intervention group
Group type: COMPARATOR
Intervention: Salvage chemotherapy
Number of subjects: 371
Study 37644897 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 10 mg
Number of subjects: 25
Study 37644897 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 20 mg
Number of subjects: 25
Study 37644897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 35089501 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Management Training combined with Coping Power Program (CPP)
Number of subjects: 0
Study 35089501 — intervention group
Group type: COMPARATOR
Intervention: Parent Management Training (PMT) only
Number of subjects: 0
Study 33326356 — intervention group
Group type: EXPERIMENTAL
Intervention: ALIS+GBT (590 mg once-daily for 12 months)
Number of subjects: 163
Study 33326356 — intervention group
Group type: EXPERIMENTAL
Intervention: ALIS+GBT
Number of subjects: 163
Study 32569757 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) active stimulation during year one
Number of subjects: 500
Study 32569757 — intervention group
Group type: COMPARATOR
Intervention: Delayed stimulation after year one (Control)
Number of subjects: 500
Study 32569757 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 500
Study 34325483 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal and early preventive medication (W+P)
Number of subjects: 120
Study 34325483 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventives with potential withdrawal therapy after 6 months (P+pW)
Number of subjects: 120
Study 34325483 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal with delayed potential preventives (W+pP)
Number of subjects: 120
Study 34325483 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment effect (all groups combined)
Number of subjects: 120
Study 34325483 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic headache after 1 year
Number of subjects: 120
Study 34325483 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of chronic headache
Number of subjects: 120
Study 32252983 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up
Number of subjects: 200
Study 32252983 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up
Number of subjects: 200
Study 33221559 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 gm if body weight <90 kg, 1.5 g if body weight >90 kg)
Number of subjects: 200
Study 33221559 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 ml of distilled water in 15 ml of 5% dextrose)
Number of subjects: 200
Study 33221559 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 200
Study 33221559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 32622904 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory loading (IL) of 41 cm H2O (∼30 % of maximal inspiratory pressure)
Number of subjects: 10
Study 32622904 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory loading (IL)
Number of subjects: 10
Study 37100921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 0
Study 37100921 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil infusion
Number of subjects: 0
Study 33486657 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate freezing after operation (Group 1)
Number of subjects: 16
Study 33486657 — intervention group
Group type: COMPARATOR
Intervention: Cooling to 5 °C for 24 hours before freezing (Group 2)
Number of subjects: 16
Study 32610342 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cord clamping (≤10 s)
Number of subjects: 400
Study 32610342 — intervention group
Group type: COMPARATOR
Intervention: Delayed cord clamping (≥180 s)
Number of subjects: 400
Study 33053279 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 (lipid nanoparticle-formulated, nucleoside-modified RNA vaccine candidate)
Number of subjects: 195
Study 33053279 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b1 (lipid nanoparticle-formulated, nucleoside-modified RNA vaccine candidate)
Number of subjects: 195
Study 33053279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 35907513 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg by mouth 3 times a day for 30-36 months
Number of subjects: 83
Study 32948827 — intervention group
Group type: EXPERIMENTAL
Intervention: bissap tablets (2 × 375 mg/day)
Number of subjects: 219
Study 32948827 — intervention group
Group type: EXPERIMENTAL
Intervention: bissap brew (10 g of calyx/day)
Number of subjects: 219
Study 32948827 — intervention group
Group type: EXPERIMENTAL
Intervention: kinkeliba tablets (2 × 200 mg/day)
Number of subjects: 219
Study 32948827 — intervention group
Group type: EXPERIMENTAL
Intervention: kinkeliba brew (10 g of leaves/day)
Number of subjects: 219
Study 32948827 — intervention group
Group type: COMPARATOR
Intervention: captopril (2 × 50 mg/day)
Number of subjects: 219
Study 35695316 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical-radiomics model
Number of subjects: 522
Study 35695316 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical-radiomics nomogram
Number of subjects: 522
Study 33443933 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administered before surgery and at various time points postoperatively.
Number of subjects: 41
Study 33443933 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered before surgery and at various time points postoperatively.
Number of subjects: 41
Study 33443933 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral TXA (1g) taken by healthy volunteers.
Number of subjects: 41
Study 32943033 — intervention group
Group type: COMPARATOR
Intervention: High-risk group based on risk score
Number of subjects: 0
Study 32943033 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on survival-related genes
Number of subjects: 0
Study 35605268 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg and cetylpyridinium chloride 1.00 mg in the form of tablets for resorption
Number of subjects: 266
Study 35605268 — intervention group
Group type: COMPARATOR
Intervention: Cetylpyridinium chloride 1.2 mg in the form of medicinal lozenges
Number of subjects: 266
Study 34207221 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy product (HD) consumption (≥4 servings/day)
Number of subjects: 27
Study 34207221 — intervention group
Group type: COMPARATOR
Intervention: Adequate dairy product (AD) consumption (≤2 servings/day)
Number of subjects: 27
Study 34368999 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 GBq radioactive iodine (RAI) ablation
Number of subjects: 506
Study 34368999 — intervention group
Group type: COMPARATOR
Intervention: 3.7 GBq radioactive iodine (RAI) ablation
Number of subjects: 506
Study 32616022 — intervention group
Group type: EXPERIMENTAL
Intervention: Data linkage consent
Number of subjects: 9232
Study 32616022 — intervention group
Group type: EXPERIMENTAL
Intervention: Successfully linked students
Number of subjects: 9232
Study 32616022 — intervention group
Group type: COMPARATOR
Intervention: Mental health diagnoses
Number of subjects: 9232
Study 32616022 — intervention group
Group type: COMPARATOR
Intervention: Specialist contacts
Number of subjects: 9232
Study 36349428 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI neurofeedback (fMRI‐NF) of the right inferior frontal cortex (rIFC)
Number of subjects: 88
Study 36349428 — intervention group
Group type: COMPARATOR
Intervention: Sham fMRI neurofeedback
Number of subjects: 88
Study 33406859 — intervention group
Group type: EXPERIMENTAL
Intervention: C. nebraskensis inoculation at V6 to V10 on susceptible hybrid
Number of subjects: 6
Study 33406859 — intervention group
Group type: EXPERIMENTAL
Intervention: C. nebraskensis inoculation at V6 to V10 on moderately susceptible hybrid
Number of subjects: 6
Study 33406859 — intervention group
Group type: EXPERIMENTAL
Intervention: C. nebraskensis inoculation on resistant hybrid
Number of subjects: 6
Study 33406859 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in R1 disease severity on susceptible hybrid
Number of subjects: 6
Study 33406859 — intervention group
Group type: COMPARATOR
Intervention: Noninoculated control
Number of subjects: 6
Study 33406859 — intervention group
Group type: EXPERIMENTAL
Intervention: C. nebraskensis inoculation at reproductive silk stage (R1)
Number of subjects: 6
Study 32846782 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg dexamethasone (4 mL) intravenously just after anesthesia and repeated at 24 hours after surgery
Number of subjects: 80
Study 32846782 — intervention group
Group type: COMPARATOR
Intervention: 10 mg dexamethasone (2 mL) intravenously just after anesthesia and repeated at 24 hours after surgery
Number of subjects: 80
Study 34175463 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal policy of preventive stoma (LPS)
Number of subjects: 363
Study 34175463 — intervention group
Group type: COMPARATOR
Intervention: Restrictive policy of preventive stoma (RPS)
Number of subjects: 363
Study 34175463 — intervention group
Group type: EXPERIMENTAL
Intervention: Without stoma at RPS center
Number of subjects: 363
Study 34175463 — intervention group
Group type: EXPERIMENTAL
Intervention: With stoma at RPS center
Number of subjects: 363
Study 34175463 — intervention group
Group type: EXPERIMENTAL
Intervention: Without stoma at LPS center
Number of subjects: 363
Study 34175463 — intervention group
Group type: EXPERIMENTAL
Intervention: With stoma at LPS center
Number of subjects: 363
Study 34175463 — intervention group
Group type: EXPERIMENTAL
Intervention: Performing rectal sutures within 8 cm from the anal verge
Number of subjects: 363
Study 33126534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cynara scolymus (Cs) extract supplementation
Number of subjects: 54
Study 35759976 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle Human Touch (GHT)
Number of subjects: 50
Study 35759976 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 33648834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium 4-phenylbutyrate (NaPB) high dose (4.3 g/m2) administered pre-breakfast
Number of subjects: 20
Study 33648834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium 4-phenylbutyrate (NaPB) low dose (1.4 g/m2) administered pre-breakfast
Number of subjects: 20
Study 33648834 — intervention group
Group type: COMPARATOR
Intervention: Sodium 4-phenylbutyrate (NaPB) administered post-breakfast (both doses)
Number of subjects: 20
Study 32198642 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone (AA) with statin and vitamin D
Number of subjects: 0
Study 32198642 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone (AA) alone
Number of subjects: 0
Study 32198642 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone (AA) plus statin plus vitamin D
Number of subjects: 0
Study 35863990 — intervention group
Group type: EXPERIMENTAL
Intervention: Single CO2 laser treatment
Number of subjects: 119
Study 35863990 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 119
Study 33854307 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance Exercise Training (HIT-RT) for 18 months
Number of subjects: 43
Study 33854307 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance Exercise Training (HIT-RT) followed by 6 months of detraining
Number of subjects: 43
Study 33854307 — intervention group
Group type: COMPARATOR
Intervention: Control Group (non-training)
Number of subjects: 43
Study 34158598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus endocrine therapy (RIB + ET)
Number of subjects: 818
Study 35831046 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed consent after in‐person assessment for health data
Number of subjects: 2110
Study 35831046 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent consent during in‐person assessment for health data
Number of subjects: 2110
Study 35831046 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed consent after in‐person assessment for education data
Number of subjects: 2110
Study 35831046 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent consent during in‐person assessment for education data
Number of subjects: 2110
Study 35831046 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined consent for health and education data
Number of subjects: 2110
Study 35831046 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate consent for health and education data
Number of subjects: 2110
Study 35831046 — intervention group
Group type: COMPARATOR
Intervention: Control groups with a baseline consent rate of 90%
Number of subjects: 2110
Study 33010045 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization‐Based Treatment (MBT)
Number of subjects: 75
Study 33010045 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 75
Study 35284808 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 µg
Number of subjects: 210
Study 35284808 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 µg + CpG1018
Number of subjects: 210
Study 35284808 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 µg
Number of subjects: 210
Study 35284808 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 µg + CpG1018
Number of subjects: 210
Study 35284808 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg
Number of subjects: 210
Study 35284808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 33156761 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert® MTB/RIF
Number of subjects: 72985